JP2024537137A5 - - Google Patents
Info
- Publication number
- JP2024537137A5 JP2024537137A5 JP2024520703A JP2024520703A JP2024537137A5 JP 2024537137 A5 JP2024537137 A5 JP 2024537137A5 JP 2024520703 A JP2024520703 A JP 2024520703A JP 2024520703 A JP2024520703 A JP 2024520703A JP 2024537137 A5 JP2024537137 A5 JP 2024537137A5
- Authority
- JP
- Japan
- Prior art keywords
- kras
- inhibitor
- cancer
- salt
- sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252405P | 2021-10-05 | 2021-10-05 | |
| US63/252,405 | 2021-10-05 | ||
| PCT/US2022/045625 WO2023059600A1 (en) | 2021-10-05 | 2022-10-04 | Combinations of kras g12d inhibitors with irinotecan and related methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537137A JP2024537137A (ja) | 2024-10-10 |
| JP2024537137A5 true JP2024537137A5 (https=) | 2025-09-30 |
Family
ID=85803676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520703A Pending JP2024537137A (ja) | 2021-10-05 | 2022-10-04 | Ｋｒａｓ ｇ１２ｄ阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250249003A1 (https=) |
| EP (1) | EP4412720A4 (https=) |
| JP (1) | JP2024537137A (https=) |
| KR (1) | KR20240073115A (https=) |
| CN (1) | CN118354794A (https=) |
| AU (1) | AU2022361219A1 (https=) |
| CA (1) | CA3233571A1 (https=) |
| IL (1) | IL311863A (https=) |
| MX (1) | MX2024004214A (https=) |
| WO (1) | WO2023059600A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
-
2022
- 2022-10-04 AU AU2022361219A patent/AU2022361219A1/en active Pending
- 2022-10-04 CN CN202280077625.0A patent/CN118354794A/zh active Pending
- 2022-10-04 JP JP2024520703A patent/JP2024537137A/ja active Pending
- 2022-10-04 KR KR1020247015024A patent/KR20240073115A/ko active Pending
- 2022-10-04 CA CA3233571A patent/CA3233571A1/en active Pending
- 2022-10-04 EP EP22879177.8A patent/EP4412720A4/en active Pending
- 2022-10-04 MX MX2024004214A patent/MX2024004214A/es unknown
- 2022-10-04 IL IL311863A patent/IL311863A/en unknown
- 2022-10-04 US US18/695,032 patent/US20250249003A1/en active Pending
- 2022-10-04 WO PCT/US2022/045625 patent/WO2023059600A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537140A5 (https=) | ||
| JP2024537137A5 (https=) | ||
| JP2022548791A5 (https=) | ||
| JP2024537139A5 (https=) | ||
| JP2025000632A5 (https=) | ||
| JP2025000630A5 (https=) | ||
| JP2024537136A5 (https=) | ||
| JP2025000629A5 (https=) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| JP2024540839A5 (https=) | ||
| CN105311030B (zh) | 用于抗肿瘤的螺取代化合物 | |
| CA2758300C (en) | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents | |
| ES2818110T3 (es) | Tratamiento del cáncer con una combinación que comprende dinaciclib | |
| JP2024521788A5 (https=) | ||
| JP2025512999A5 (https=) | ||
| JP2023540809A5 (https=) | ||
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| JP2019516718A5 (https=) | ||
| IL311863A (en) | Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods | |
| JP2022535577A5 (https=) | ||
| JP2012067116A5 (https=) | ||
| CN101669941B (zh) | 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物 | |
| TW201908317A (zh) | 使用parp抑制劑、替莫唑胺及/或放射療法的組合治療癌症 | |
| JP2022530866A5 (https=) | ||
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 |